levothyroxine sodium 0.125 MG/ML Oral Solution [Tirosint]
- RxCUI
- 2056490
- RxNorm name
- levothyroxine sodium 0.125 MG/ML Oral Solution [Tirosint]
- Display name
- TIROSINT (Oral Liquid)
- Full name
- levothyroxine sodium 0.125 MG/ML Oral Solution [Tirosint]
- Term type
- SBD
- Status
- Active
- Strength
- 0.125 mg/ml
- Dose form
- Sol
- Route
- Oral Liquid
- Updated
- 2026-11-08 10:16:44
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 102018
- Active start
- 102018
- Multiple ingredient
- NO
- Branded
- YES
Ingredients And Strength#
| Ingredient | Strength | Base | Basis of strength |
|---|---|---|---|
| levothyroxine sodium | 0.125 MG / 1 ML | levothyroxine | levothyroxine sodium |
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Oral Solution | 316968 |
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| levothyroxine | 10582 |
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | Tirosint SOL 0.125 MG per 1 ML Oral Solution | 1 | NAMES |
| RxNorm Name | levothyroxine sodium 0.125 MG/ML Oral Solution [Tirosint] | 1 | NAMES |
| RxNorm Synonym | Tirosint SOL 0.125 MG per 1 ML Oral Solution | 1 | NAMES |
| TTY | SBD | 1 | ATTRIBUTES |
| SPL_SET_ID | 5d378add-f13d-40f2-99dc-0f2340ab44b7 | 1 | CODES |
| RxCUI | 2056490 | 1 | CODES |
| MMSL_CODE | BD31430 | 1 | CODES |
FDA NDC Products And Packages#
| Package NDC | Product NDC | Name | Labeler | Application |
|---|---|---|---|---|
| 71858-0140-2 | 71858-0140 | Tirosint Levothyroxine Sodium | IBSA Pharma Inc. | NDA206977 |
| 71858-0140-5 | 71858-0140 | Tirosint Levothyroxine Sodium | IBSA Pharma Inc. | NDA206977 |
Drugs@FDA Applications#
| Application | NDC | Name | Marketing category | Labeler |
|---|---|---|---|---|
| NDA206977 | 71858-0140 | Tirosint Levothyroxine Sodium | NDA | IBSA Pharma Inc. |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tirosint SOL | LEVOTHYROXINE SODIUM | IBSA Pharma Inc. | 5d378add-f13d-40f2-99dc-0f2340ab44b7 | 2026-03-27 | Boxed warning, Warnings, Adverse reactions | 71858-0140-5 71858-0140-2 71858-0140 71858014006 71858014005 71858014001 71858014002 71858014004 2056490 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 5d378add-f13d-40f2-99dc-0f2340ab44b7 | TIROSINT - SOL 125 MCG in 1 mL Oral Solution [PSN] · levothyroxine sodium 0.125 MG/ML Oral Solution [Tirosint] [SBD] · Tirosint SOL 0.125 MG per 1 ML Oral Solution [SY] | 3 | 18 | These highlights do not include all the information needed to use TIROSINT ® -SOL safely and effectively. See full prescribing information for TIROSINT ® -SOL. Initial U.S. Approval: 2000 | 20260327 |
Recently Linked DailyMed Labels#
| Set ID | Title | Manufacturer | Effective |
|---|---|---|---|
| 5d378add-f13d-40f2-99dc-0f2340ab44b7 | These highlights do not include all the information needed to use TIROSINT ® -SOL safely and effectively. See full prescribing information for TIROSINT ® -SOL. Initial U.S. Approval: 2000 | IBSA Pharma Inc. | 20260327 |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | H03AA | Thyroid hormones | ATC1-4 | levothyroxine sodium | |
| FDASPL | D013974 | Thyroxine | CHEM | has_chemical_structure | levothyroxine |
| FDASPL | N0000175945 | l-Thyroxine | EPC | has_epc | levothyroxine |
| MEDRT | D013974 | Thyroxine | CHEM | has_ingredient | levothyroxine sodium |
| MEDRT | D013974 | Thyroxine | CHEM | has_ingredient | levothyroxine |
| MEDRT | D000309 | Adrenal Insufficiency | DISEASE | ci_with | levothyroxine |
| MEDRT | D000309 | Adrenal Insufficiency | DISEASE | ci_with | levothyroxine sodium |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | levothyroxine |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | levothyroxine sodium |
| MEDRT | D006042 | Goiter | DISEASE | may_treat | levothyroxine |
| MEDRT | D006042 | Goiter | DISEASE | may_treat | levothyroxine sodium |
| MEDRT | D007037 | Hypothyroidism | DISEASE | may_prevent | levothyroxine |
| MEDRT | D007037 | Hypothyroidism | DISEASE | may_prevent | levothyroxine sodium |
| MEDRT | D009203 | Myocardial Infarction | DISEASE | ci_with | levothyroxine sodium |
| MEDRT | D009203 | Myocardial Infarction | DISEASE | ci_with | levothyroxine |
| MEDRT | D009230 | Myxedema | DISEASE | may_treat | levothyroxine sodium |
| MEDRT | D009230 | Myxedema | DISEASE | may_treat | levothyroxine |
| MEDRT | D013959 | Thyroid Diseases | DISEASE | may_diagnose | levothyroxine |
| MEDRT | D013959 | Thyroid Diseases | DISEASE | may_diagnose | levothyroxine sodium |
| MEDRT | D013964 | Thyroid Neoplasms | DISEASE | may_treat | levothyroxine |
| MEDRT | D013964 | Thyroid Neoplasms | DISEASE | may_treat | levothyroxine sodium |
| MEDRT | D013967 | Thyroiditis, Autoimmune | DISEASE | may_treat | levothyroxine sodium |
| MEDRT | D013967 | Thyroiditis, Autoimmune | DISEASE | may_treat | levothyroxine |
| MEDRT | D013971 | Thyrotoxicosis | DISEASE | may_treat | levothyroxine |
| MEDRT | D013971 | Thyrotoxicosis | DISEASE | ci_with | levothyroxine sodium |
| MEDRT | D013971 | Thyrotoxicosis | DISEASE | may_treat | levothyroxine sodium |
| MEDRT | D013971 | Thyrotoxicosis | DISEASE | ci_with | levothyroxine |
| MEDRT | N0000000237 | Thyroid Hormone Receptor Agonists | MOA | has_moa | levothyroxine |
| MEDRT | N0000000237 | Thyroid Hormone Receptor Agonists | MOA | has_moa | levothyroxine sodium |
| MEDRT | N0000008347 | Cellular Synthetic Activity Alteration | PE | has_pe | levothyroxine |
| MEDRT | N0000008347 | Cellular Synthetic Activity Alteration | PE | has_pe | levothyroxine sodium |
| MEDRT | N0000009340 | Increased Gluconeogenesis | PE | has_pe | levothyroxine |
| MEDRT | N0000009340 | Increased Gluconeogenesis | PE | has_pe | levothyroxine sodium |
| MEDRT | N0000009399 | Increased Metabolic Rate | PE | has_pe | levothyroxine |
| MEDRT | N0000009399 | Increased Metabolic Rate | PE | has_pe | levothyroxine sodium |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | AVAILABLE_STRENGTH | 0.125 MG/ML |
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | HUMAN_DRUG | US |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | SCHEDULE | 0 |
| CODES | NDA | NDA206977 |
| NAMES | Prescribable Synonym | TIROSINT - SOL 125 MCG in 1 mL Oral Solution |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Micromedex RED BOOK |
| SOURCES | Source | Multum MediSource Lexicon |